Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Revenue - OtherShares OutstandingShares Outstanding
Ratios

Lyra Therapeutics (LYRA) Shares Outstanding (2021 - 2025)

Lyra Therapeutics has reported Shares Outstanding over the past 5 years, most recently at $1.8 million for Q4 2025.

  • Quarterly results put Shares Outstanding at $1.8 million for Q4 2025, up 35.46% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (up 35.46% YoY), and the annual figure for FY2025 was $1.8 million, up 35.46%.
  • Shares Outstanding for Q4 2025 was $1.8 million at Lyra Therapeutics, up from $1.6 million in the prior quarter.
  • Over the last five years, Shares Outstanding for LYRA hit a ceiling of $49.5 million in Q3 2023 and a floor of $1.1 million in Q4 2023.
  • Median Shares Outstanding over the past 5 years was $13.0 million (2021), compared with a mean of $15.2 million.
  • Biggest five-year swings in Shares Outstanding: surged 144.8% in 2022 and later crashed 97.36% in 2024.
  • Lyra Therapeutics' Shares Outstanding stood at $13.0 million in 2021, then soared by 144.69% to $31.8 million in 2022, then tumbled by 96.4% to $1.1 million in 2023, then increased by 14.51% to $1.3 million in 2024, then skyrocketed by 35.46% to $1.8 million in 2025.
  • The last three reported values for Shares Outstanding were $1.8 million (Q4 2025), $1.6 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.